---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-23-000033"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T12:15:38.309852+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Halozyme stockholders elect three Class I directors and approve 2023 auditor at annual meeting

## Summary
- All three Class I director nominees elected: Connaughton, Miyashita, Posard, with majority votes.
- Advisory vote on executive compensation approved with 107.6M for vs 4.7M against (95.8% support).
- Stockholders chose annual frequency for future advisory votes on executive compensation (110.4M for one year).
- Ratification of Ernst & Young as auditor for FY2023 approved with 123.3M votes for (98.8% of votes cast).
- Turnout: 124.5M shares represented out of 135.4M outstanding (92% attendance).

## SEC filing metadata
- accession: 0001159036-23-000033
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/0001159036-23-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/halo-20230505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-23-000033
- JSON: https://secwatch.observer/filing/0001159036-23-000033.json
- Plain text: https://secwatch.observer/filing/0001159036-23-000033.txt

## Key facts
- Shareholder Votes
  HALOZYME THERAPEUTICS, INC. shareholders approved The advisory vote on the frequency of holding future advisory votes on the compensation of the Company’s named executive officers at the 2023-05-05 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2023-05-05
  source text: Proposal 3 : The advisory vote on the frequency of holding future advisory votes on the compensation of the Company’s named executive officers was as follows: One Year Two Years Three Years Abstain 110,411,006 145,264 1,760,124 83,512
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/0001159036-23-000033-index.htm
- Shareholder Votes
  HALOZYME THERAPEUTICS, INC. shareholders approved A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-05 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-05
  source text: Proposal 4 : The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 was as follows: Votes For Votes Against Abstain Broker Non-Votes 123,271,829 1,153,279 103,055 — The foregoing proposal was approved.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/0001159036-23-000033-index.htm
- Shareholder Votes
  HALOZYME THERAPEUTICS, INC. shareholders approved The advisory vote on the compensation of the Company's named executive officers at the 2023-05-05 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-05
  source text: Proposal 2 : The advisory vote on the compensation of the Company's named executive officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 107,628,112 4,657,698 114,096 12,128,257 The foregoing proposal was approved.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/0001159036-23-000033-index.htm
- Shareholder Votes
  HALOZYME THERAPEUTICS, INC. shareholders approved Election of three Class I directors to hold office for a three-year term expiring at the 2026 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified at the 2023-05-05 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-05
  source text: On May 5, 2023, Halozyme Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/0001159036-23-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.